Nisa Investment Advisors’s Prelude Therapeutics PRLD Stock Holding History

Nisa Investment Advisors’s Portfolio PRLD Stock Details PRLD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$5.59K	Hold	1,634	–	–	﹤0.01%	2430
2025 Q4	$4.74K	Hold	1,634	–	–	﹤0.01%	2459
2025 Q3	$2.35K	Hold	1,634	–	–	﹤0.01%	2587
2025 Q2	$1.32K	Buy	1,634 +1,234	+309%	+$1.07K	﹤0.01%	2688
2025 Q1	$307	Sell	400 -108	-21%	-$101	﹤0.01%	2868
2024 Q4	$648	Buy	+508	New	+$674	﹤0.01%	2773
2024 Q3	–	Sell	-2,100	Closed	-$8K	–	3026
2024 Q2	$8K	Buy	+2,100	New	+$8.55K	﹤0.01%	2203
2023 Q4	–	Sell	-37	Closed	-$114	–	2725
2023 Q3	$114	Sell	37 -3,963	-99%	-$14.9K	﹤0.01%	2728
2023 Q2	$18K	Hold	4,000	–	–	﹤0.01%	2134
2023 Q1	$23K	Hold	4,000	–	–	﹤0.01%	1968
2022 Q4	$24K	Hold	4,000	–	–	﹤0.01%	2014
2022 Q3	$27K	Hold	4,000	–	–	﹤0.01%	1970
2022 Q2	$21K	Buy	+4,000	New	+$20.4K	﹤0.01%	2041

Other funds holding PRLD

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

SFM

Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Nisa Investment Advisors's PRLD Position: Q1 2026 in Review

Nisa Investment Advisors held its Prelude Therapeutics (PRLD) position steady in Q1 2026 at 1,634 shares worth $5.59K. The position accounts for ﹤0.01% of the portfolio, ranked #2430.

Nisa Investment Advisors first reported a position in PRLD in Q2 2022 and has held it in 13 quarters since. The position peaked at $27K in Q3 2022. 55 funds tracked by Wall St. Rank hold PRLD as of Q1 2026.

Nisa Investment Advisors held 1,634 shares of Prelude Therapeutics worth $5.59K as of Q1 2026.
Nisa Investment Advisors left its Prelude Therapeutics share count unchanged in Q1 2026.
Prelude Therapeutics made up ﹤0.01% of Nisa Investment Advisors's portfolio in Q1 2026, its #2430 holding.
Nisa Investment Advisors first reported a position in Prelude Therapeutics in Q2 2022 and has held it in 13 quarters since.
Nisa Investment Advisors's Prelude Therapeutics position peaked at $27K in Q3 2022.
55 funds tracked by Wall St. Rank held Prelude Therapeutics as of Q1 2026.

Based on Nisa Investment Advisors's 13F filing for Q1 2026, filed 30 Apr 2026.